Bravo, here is your Joe FB quote from last week, w
Post# of 36537
(Total Views: 262)
Posted On: 05/14/2020 6:11:53 PM
Bravo, here is your Joe FB quote from last week, without your added comments:
——————————
Joseph Moscato
Chris please your facts are ridiculous, hospitals don’t fill up with only one disease and trust me I have an open end federal purchase order for my fda approved product with all 165 VA hospitals and every single one is full and every one is only doing Corona, that’s has never happened in health care in the last 100 years since Spanish flu, so stop!
——————————
It’s pretty clear in my mind that this is a classic Joe run-on sentence, where he flips from one lane in his thinking to another without putting on his signal. Joe is telling Chris that GNBT has the open end purchase order (BPA) from the FDA, and it is ridiculous for Chris to tell him every single VA hospital is full and only doing Corona-related care, because “that’s has never happened in health care in the last 100 years since Spanish flu, so stop” saying that’s the case now.
I don’t know if he was actually able to get Excellagen rolled out to more sites/doctors with CV taking so much of the focus. But I am confident he was saying it was ridiculous to say he couldn’t move forward with the rollout.
Someone commented that the VA wouldn’t stop treating non-CV patients, including wound victims. That is certainly true. But, for all we know, they continued using established treatments at most sites instead of a new and better option (Excellagen) simply because they weren’t trained and familiar with Excellagen... and they didn’t want to risk bringing in more people to train on Excellagen to avoid CV transmission risk and the additional complications of dealing with a new treatment.
Cody - I appreciate your comment today about focusing on the things GNBT can control. Excellagen was SUPPOSED to be one of those items. With the BPA, it appeared we had an FDA-approved, VA-authorized product that we were manufacturing successfully and inexpensively. This product was on the road to being our first real revenue (and cash flow) producing product of this “Nu” era.
Enter CV, and we are possibly behind the 8-ball again. I hope Joe was right and “Chris” was wrong, and Joe was able to finally start generating some revs and cash flow from Excellagen in FQ3. I guess we will see on June 15 (or 5 days later w our “standard” late filing extension)...
——————————
Joseph Moscato
Chris please your facts are ridiculous, hospitals don’t fill up with only one disease and trust me I have an open end federal purchase order for my fda approved product with all 165 VA hospitals and every single one is full and every one is only doing Corona, that’s has never happened in health care in the last 100 years since Spanish flu, so stop!
——————————
It’s pretty clear in my mind that this is a classic Joe run-on sentence, where he flips from one lane in his thinking to another without putting on his signal. Joe is telling Chris that GNBT has the open end purchase order (BPA) from the FDA, and it is ridiculous for Chris to tell him every single VA hospital is full and only doing Corona-related care, because “that’s has never happened in health care in the last 100 years since Spanish flu, so stop” saying that’s the case now.
I don’t know if he was actually able to get Excellagen rolled out to more sites/doctors with CV taking so much of the focus. But I am confident he was saying it was ridiculous to say he couldn’t move forward with the rollout.
Someone commented that the VA wouldn’t stop treating non-CV patients, including wound victims. That is certainly true. But, for all we know, they continued using established treatments at most sites instead of a new and better option (Excellagen) simply because they weren’t trained and familiar with Excellagen... and they didn’t want to risk bringing in more people to train on Excellagen to avoid CV transmission risk and the additional complications of dealing with a new treatment.
Cody - I appreciate your comment today about focusing on the things GNBT can control. Excellagen was SUPPOSED to be one of those items. With the BPA, it appeared we had an FDA-approved, VA-authorized product that we were manufacturing successfully and inexpensively. This product was on the road to being our first real revenue (and cash flow) producing product of this “Nu” era.
Enter CV, and we are possibly behind the 8-ball again. I hope Joe was right and “Chris” was wrong, and Joe was able to finally start generating some revs and cash flow from Excellagen in FQ3. I guess we will see on June 15 (or 5 days later w our “standard” late filing extension)...
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼